PRESS RELEASE DUBLIN.

Howson, John A. King, Jiri Michal and Andrew L. Turner, effective upon the close of the deal. The addition of Michael and Peter brings significant knowledge from Allergan to your Board, and I welcome their expertise and insights as we combine our two dynamic organizations, said Brent Saunders, President and CEO of Actavis. I wish to thank the complete Allergan Board for his or her stewardship to Allergan shareholders in creating a strong and successful company. I also desire to thank Tamar, John, and Jiri for serving on our Plank since the acquisition of Warner Chilcott and guiding the foundational mixture that expanded Actavis' placement of leadership in essential brand therapeutic categories, and also Andy Turner, whose years of service, including as Chairman of the Board previously, have been instrumental as we have dramatically reshaped our Company.Additionally, 56 percent of treated individuals experienced disease control . Reductions in tumor burden were observed in patients infected with different ‘high risk’ strains of HPV including HPV16, 18, 31, 33, 35, and 45. ‘The tolerability of ADXS-HPV only or in combination with chemotherapy, the target tumor responses, and the effect upon survival in this past due stage, poor prognosis affected individual population shows that ADXS-HPV may have clinical warrants and utility additional investigation,’ commented Dr. John Rothman, Executive Vice President of Operations and Science at Advaxis.